News | October 23, 2006

Surgery Found to be Less Risky than Stents

When it comes to opening blocked carotid arteries, surgery may be less risky than stents according to a study by French doctors including Jean-Louis Mas, M.D., of the Hospitaux Sainte-Anne in Paris.

The carotid arteries run through the neck, taking blood to the brain. They can become narrowed from plaque buildup, making strokes more likely. Mas' team found that patients who got surgery instead of stents to open the carotid arteries were less likely to die or have strokes in the first six months after their procedure.

The study appears in The New England Journal of Medicine.

Mas' team studied 527 French patients who had a carotid artery at least 60 percent more narrow than normal. The patients had all experienced a non-disabling stroke, or "mini-stroke," because of the blockage. The researchers randomly assigned patients to get carotid artery surgery or stents.

Over the next six months, 6 percent of the surgery group died or had a stroke, compared with about 11 percent of the stent group.

They stopped the experiment early due to those findings and called for larger, longer studies to check their results.


Related Content

News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
Subscribe Now